The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Open accessAbstract
Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic drugs that have shown improvement in renal and cardiovascular outcomes in patients with kidney disease, with and without diabetes. In this review, we will describe the different proposed mechanisms of action of SGLT2i. Gliflozins inhibit renal glucose reabsorption by blocking the SGLT2 cotransporters in the proximal tubules and causing glucosuria. This reduces glycemia and lowers HbA 1c by ~1.0%. The accompanying sodium excretion reverts the tubuloglomerular feedback and reduces intraglomerular pressure, which is central to the nephroprotective effects of SGLT2i. The caloric loss reduces weight, increases insulin sensitivity, lipid metabolism, and likely reduces lipotoxicity. Metabolism shifts toward gluconeogenesis and ketogenesis, thought to be protective for the heart and kidneys. Additionally, there is evidence of a reduction in tubular cell glucotoxicity through reduced mitochondrial dysfunction and inflammation. SGLT2i likely reduce kidney hypoxia by reducing tubular energy and oxygen demand. SGLT2i improve blood pressure through a negative sodium and water balance and possibly by inhibiting the sympathetic nervous system. These changes contribute to the improvement of cardiovascular function and are thought to be central in the cardiovascular benefits of SGLT2i. Gliflozins also reduce hepcidin levels, improving erythropoiesis and anemia. Finally, other possible mechanisms include a reduction in inflammatory markers, fibrosis, podocyte injury, and other related mechanisms. SGLT2i have shown significant and highly consistent benefits in renal and cardiovascular protection. The complexity and interconnectedness of the primary and secondary mechanisms of action make them a most interesting and exciting pharmacologic group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 6×
“Another meta-analysis (59) of the EMPAREG OUTCOME, CANVAS and DECLARE-TIMI 58 trials stratified the subjects (n = 34,322) according to eGFR and demonstrated that SGLT2 inhibitors had a better effect in reducing adverse renal outcomes (worsening renal function, ESKD or death from renal cause) when eGFR is between 30 an…”
BackgroundMethodInfluentialDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 1×
“In 2019, the DECLARE-TIMI 58 (20) trial, which included over 17,000 patients followed for 4.”
BackgroundCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 5×
“Clinical trials on diabetic and non-diabetic patients with chronic kidney disease (CKD) (22, 34) have demonstrated that SGLT2 inhibitors reduce albuminuria significantly.”
BackgroundInfluentialSelf-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874 · cited 1×
“More recently the EMPERORpreserved (17) trial also demonstrated similar benefits from empagliflozin in patients with heart failure and preserved ejection fraction.”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · cited 1×
“Together with glucosuria, SGLT2 inhibition causes natriuresis that is associated with a negative salt and water balance (32).”
BackgroundRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
The tubular hypothesis of nephron filtration and diabetic kidney disease
Vallon, V., & Thomson, S. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0256-y · Cited by 465 · cited 3×
“oxygen consumption in proximal cells (8).”
BackgroundRole of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
Self-citationProbing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009) · Kidney International · doi:10.1038/ki.2009.87 · Cited by 358
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4656-5 · Cited by 348
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Santer, R., & Calado, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010609 · Cited by 343
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 308
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J. M., & Feder, J. N. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0006-4 · Cited by 307
DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293 · cited 6×
“This causes a reduction in TmaxG to around 40– 80 mg/dL (6) and a reduction in the renal threshold for glucosuria.”
BackgroundInfluentialRosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., & Iqbal, N. (2015) · Diabetes Care · doi:10.2337/dc14-1142 · Cited by 290
Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., Pollock, C., & Mather, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054442 · Cited by 277
Sano, M., Takei, M., Shiraishi, Y., & Suzuki, Y. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2760w · Cited by 252
Abdul-Ghani, M. A., DeFronzo, R. A., & Norton, L. (2013) · Diabetes · doi:10.2337/db13-0604 · Cited by 249
Del Prato, S., Nauck, M., Durán‐Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., & Parikh, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12459 · Cited by 233
O'Neill, J., Fasching, A., Pihl, L., Patinha, D., Franzén, S., & Palm, F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00689.2014 · Cited by 232
Effects of dapagliflozin in stage 4 chronic kidney disease
Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020167 · Cited by 201
Self-citationDapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Ghanim, H., Abuaysheh, S., Hejna, J., Green, K., Batra, M., Makdissi, A., Chaudhuri, A., & Dandona, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa057 · Cited by 197
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Merovci, A., Mari, A., Solis, C., Xiong, J., Daniele, G., Chavez-Velazquez, A., Tripathy, D., Urban McCarthy, S., Abdul-Ghani, M., & DeFronzo, R. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3472 · Cited by 186
Cherney, D., Lund, S. S., Perkins, B. A., Groop, P.-H., Cooper, M. E., Kaspers, S., Pfarr, E., Woerle, H. J., & von Eynatten, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4008-2 · Cited by 174
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Cassis, P., Locatelli, M., Cerullo, D., Corna, D., Buelli, S., Zanchi, C., Villa, S., Morigi, M., Remuzzi, G., Benigni, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98720 · Cited by 173
SGLT2 inhibition and kidney protection
Nespoux, J., & Vallon, V. (2018) · Clinical Science · doi:10.1042/cs20171298 · Cited by 172
Kahn, B. B., Shulman, G. I., DeFronzo, R. A., Cushman, S. W., & Rossetti, L. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115031 · Cited by 171
Jardine, M. J., Zhou, Z., Mahaffey, K. W., Oshima, M., Agarwal, R., Bakris, G., Bajaj, H. S., Bull, S., Cannon, C. P., Charytan, D. M., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019111168 · Cited by 168
McMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa‐Rotter, R., Chertow, G. M., Greene, T., Held, C., Hou, F. F., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051675 · Cited by 161
Self-citationŠkrtić, M., Yang, G. K., Perkins, B. A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., Woerle, H. J., Johansen, O. E., Broedl, U. C., Hach, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3396-4 · Cited by 159
Yaribeygi, H., Butler, A. E., Atkin, S. L., Katsiki, N., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26851 · Cited by 159
Improved glycemic control in mice lacking Sglt1 and Sglt2
Powell, D. R., DaCosta, C. M., Gay, J., Ding, Z.-M., Smith, M., Greer, J., Doree, D., Jeter-Jones, S., Mseeh, F., Rodriguez, L. A., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00439.2012 · Cited by 158
Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition
Layton, A. T., Vallon, V., & Edwards, A. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00007.2015 · Cited by 142
Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J. (2021) · Journal of Immunology Research · doi:10.1155/2021/9944880 · Cited by 139
Layton, A. T., Vallon, V., & Edwards, A. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00543.2015 · Cited by 139
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Abdul‐Ghani, M. A., Norton, L., & DeFronzo, R. A. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0275-6 · Cited by 135
Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet
Takagi, S., Li, J., Takagaki, Y., Kitada, M., Nitta, K., Takasu, T., Kanasaki, K., & Koya, D. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12802 · Cited by 129
Korbut, A. I., Taskaeva, I. S., Bgatova, N. P., Muraleva, N. A., Орлов, Н. Б., Dashkin, M. V., Khotskina, А. S., Zavyalov, E. L., Konenkov, V. I., Klein, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082987 · Cited by 119
Adachi, T., Yasuda, K., Okamoto, Y., Shihara, N., Oku, A., Ueta, K., Kitamura, K., Saito, A., Iwakura, T., Yamada, Y., et al. (2000) · Metabolism · doi:10.1053/meta.2000.7729 · Cited by 87
Correction of anemia by dapagliflozin in patients with type 2 diabetes
Stefánsson, B. V., Heerspink, H. J. L., Wheeler, D. C., Sjöström, C. D., Greasley, P. J., Sartipy, P., Cain, V. A., & Correa‐Rotter, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107729 · Cited by 50
Self-citationEmpagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells
Pirklbauer, M., Sallaberger, S., Staudinger, P., Corazza, U., Leierer, J., Mayer, G. J., & Schramek, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105089 · Cited by 32
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
Yasuda, K., Okamoto, Y., Nunoi, K., Adachi, T., Shihara, N., Tamon, A., Suzuki, N., Mukai, E., Fujimoto, S., Oku, A., et al. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-26714 · Cited by 15
Cited by
Rageh, A. H., Abdel-aal, F. A. M., Farrag, S. A., & Ali, A.-M. B. H. (2024) · Talanta · doi:10.1016/j.talanta.2023.124950 · Cited by 38
Mes, J. J., van den Belt, M., van der Haar, S., Oosterink, E., Luijendijk, T., Manusama, K., van Dam, L., de Bie, T., Witkamp, R., & Esser, D. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119756 · Cited by 13
Metadata
- Authors
- Fonseca-Correa, J. I., & Correa-Rotter, R.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2021-12-20
- Volume
- 8
- Pages
- 777861-777861
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W4200184795
- Cited by
- 277
- References
- 64
- FWCI
- 21.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.